Sophie Duraffour

Sophie Duraffour

Auto-generated profile, based on publicly available information

Sophie Duraffour

Department of Virology, Bernhard Nocht Institute for Tropical Medicine (BNITM), Hamburg, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2019 in Science
Verified
Journal Article
Closed access
PDF file
LKL. E. Kafetzopoulou
L. E. Kafetzopoulou
SPSteven T Pullan
Steven T Pullan
PLPhilippe Lemey
Philippe Lemey
MSM. A. Suchard
M. A. Suchard
DEDeborah Ehichioya
Deborah Ehichioya
SDS. Duraffour
S. Duraffour
Mobile detection of Lassa virus: Lassa fever is a hemorrhagic viral disease endemic to West Africa. Usually, each year sees only a smattering of cases reported, but hospitalized patients risk a 15% chance of death. Responding to fears that a 10-fold surge in cases in Nigeria in 2018 signaled an incipient outbreak, Kafetzopoulou et al. performed metagenomic nanopore sequencing directly from samples from 120 patients (see the Perspective by Bhadelia). Results showed no strong evidence of a new strain emerging nor of person-to-person transmission; rather, rodent contamination was the main source. To prevent future escalation of this disease, we need to understand what triggers the irruption of rodents into human dwellings. Science , this issue p. 74 ; see also p. 30

30 June 2022 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
FKFara R. Koundouno
Fara R. Koundouno
LKLiana E. Kafetzopoulou
Liana E. Kafetzopoulou
MFMartin Faye
Martin Faye
ARAnnick Renevey
Annick Renevey
BSBarrè Soropogui
Barrè Soropogui
NMN’fAly Magassouba
N’fAly Magassouba
On August 2, 2021, a 46-year-old man from Temessadou M’Boké, a village in Guéckédou prefecture in Guinea, died after hemorrhaging from several natural orifices. On August 3, an initial diagnosis of Marburg virus (MARV) infection was made after real-time reverse-transcriptase–polymerase-chain-reaction testing of a postmortem buccal sample obtained from the patient was performed and revealed a cycle-threshold value of 13.4 ( Figure 1A ). Field investigation teams were deployed, and the diagnostic finding was validated in two additional laboratories within a few days. In-country metagenomic next-generation sequencing allowed for full-length MARV genome recovery (99.3%), and phylogenetic analysis indicated that the new Guinea MARV strain that had been identified in the patient clustered with MARV strains isolated from bats in Sierra Leone and from humans in Angola (Fig. S1 and Table S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Close monitoring for a period of 21 days confirmed that all the patient’s contacts had remained asymptomatic, and no additional cases were detected.

1 January 2022 in The Lancet Microbe
Verified
Journal Article
Open access
ATAnke Thielebein
Anke Thielebein
YIYemisi Ighodalo
Yemisi Ighodalo
ATAbubakar Taju
Abubakar Taju
TOThomas Olokor
Thomas Olokor
RORacheal Omiunu
Racheal Omiunu
EOEphraim Ogbaini-Emovon
Ephraim Ogbaini-Emovon
There is anecdotal evidence for Lassa virus persistence in body fluids. We aimed to investigate various body fluids after recovery from acute Lassa fever, describe the dynamics of Lassa virus RNA load in seminal fluid, and assess the infectivity of seminal fluid. In this prospective, longitudinal, cohort study we collected plasma, urine, saliva, lacrimal fluid, vaginal fluid, and seminal fluid from Lassa fever survivors from Irrua Specialist Teaching Hospital in Edo State, Nigeria. Inclusion criteria for participants were RT-PCR-confirmed Lassa fever diagnosis and age 18 years or older. Samples were taken at discharge from hospital (month 0) and at months 0·5, 1, 3, 6, 9, 12, 18, and 24 after discharge. The primary objective of this study was to quantitatively describe virus persistence and clearance and assess the infectivity of seminal fluid. Lassa virus RNA was detected using real-time RT-PCR. Infectivity was tested in cell culture and immunosuppressed mice. We used a linear mixed-effect model to analyse the dynamics of virus persistence in seminal fluid over time. Between Jan 31, 2018, and Dec 11, 2019, 165 participants were enrolled in the study, of whom 159 were eligible for analysis (49 women and 110 men). Low amounts of Lassa virus RNA were detected at month 0 in plasma (49 [45%] of 110 participants), urine (37 [34%]), saliva (five [5%]), lacrimal fluid (ten [9%]), and vaginal fluid (seven [21%] of 33 female participants). Virus RNA was cleared from these body fluids by month 3. However, 35 (80%) of 44 male participants had viral RNA in seminal fluid at month 0 with a median cycle threshold of 26·5. Lassa virus RNA remained detectable up to month 12 in seminal fluid. Biostatistical modelling estimated a clearance rate of 1·19 log10 viral RNA copies per month and predicted that 50% of male survivors remain Lassa virus RNA-positive in seminal fluid for 83 days after hospital discharge and 10% remain positive in seminal fluid for 193 days after discharge. Viral RNA persistence in seminal fluid for 3 months or more was associated with higher viraemia (p=0·006), more severe disease (p=0·0075), and longer hospitalisation during the acute phase of Lassa fever (p=0·0014). Infectious virus was isolated from 48 (52%) of 93 virus RNA-positive seminal fluid samples collected between month 0 and 12. Lassa virus RNA is shed in various body fluids after recovery from acute disease. The persistence of infectious virus in seminal fluid implies a risk of sexual transmission of Lassa fever. German Federal Ministry of Health, German Research Foundation, Leibniz Association.

23 September 2020 in Viruses
Verified
Journal Article
Open access
PDF file
NMN’faly Magassouba
N’faly Magassouba
EKEnogo Koivogui
Enogo Koivogui
SCSory CONDE
Sory CONDE
MKMoussa Kone
Moussa Kone
MKMichel Koropogui
Michel Koropogui
EFElisabeth Fichet-Calvet
Elisabeth Fichet-Calvet
Lassa fever is a rodent-borne disease caused by Lassa virus (LASV). It causes fever, dizziness, vertigo, fatigue, coughing, diarrhea, internal bleeding and facial edema. The disease has been known in Guinea since 1960 but only anectodical acute cases have been reported to date. In January 2019, a 35-year-old man, a wood merchant from Kissidougou, Forest Guinea, presented himself at several health centers with persistent fever, frequent vomiting and joint pain. He was repeatedly treated for severe malaria, and died three weeks later in Mamou regional hospital. Differential diagnosis identified LASV as the cause of death. No secondary cases were reported. The complete LASV genome was obtained using next-generation sequencing. Phylogenetic analysis showed that this strain, namely the Kissidougou strain, belongs to the clade IV circulating in Guinea and Sierra Leone, and is thought to have emerged some 150 years ago. Due to the similarity of symptoms with malaria, Lassa fever is still a disease that is difficult to recognize and that may remain undiagnosed in health centers in Guinea.

1 June 2017 in Current Opinion in Virology
Verified
Journal Article
Open access
SDSophie Duraffour
Sophie Duraffour
DMDenis Malvy
Denis Malvy
DSDaouda Sissoko
Daouda Sissoko
The reported case fatality ratios (CFR) of Ebola virus disease (EVD) have been as high as 90% in previous outbreaks. While the cumulative CFR among patients medically evacuated and treated in Western countries was inferior to 20%, it peaked to approximately 75% between September and December 2014 in West Africa, thereafter decreasing to less than 40% (May 2015) without current evidence of major virus mutations capable to alter virus pathogenicity over the course of the epidemic. Therefore, the observed diminution of CFR is likely to reflect improvement of EVD patient care. Here, we summarize major lessons learned, that is, progresses and knowledge gaps, about the clinical management of patients in West African settings during the 2014-2016 outbreak.

15 May 2026 in Nature Medicine
Verified
Journal Article
Open access
PDF file
CECyril Erameh
Cyril Erameh
KOKevin Okwaraeke
Kevin Okwaraeke
CKChristine Kleist
Christine Kleist
OEOsahogie Edeawe
Osahogie Edeawe
NANelson Adedosu
Nelson Adedosu
MGMirjam Groger
Mirjam Groger
Lassa fever (LF) is a viral hemorrhagic fever endemic to West Africa, with high case fatality in hospitalized patients and limited treatment options, including ribavirin. Preclinical evidence suggests high-dose favipiravir is a promising antiviral treatment alternative. We conducted a randomized controlled open-label phase 2 clinical trial at two reference hospitals in Nigeria to evaluate favipiravir in the treatment of LF. Primary endpoints were the description of classic pharmacokinetic parameters (maximum plasma concentration, time to reach maximum plasma concentration, area under the curve (AUC), half-life and volume of distribution) as well as the safety and tolerability of favipiravir compared with ribavirin in the treatment of acute LF. Hospitalized adult patients with mild-to-moderate RT-PCR-confirmed LF were eligible to participate. In total, 41 patients were randomized (ribavirin n = 21; favipiravir n = 20), and 36 completed the 10-day follow-up period. A total of 19 (46.3%) participants were female, and the median age was 37 years. The primary endpoints were met. Pharmacokinetic analysis of favipiravir in a one-compartment model indicated reliable exposure with maximum plasma concentration of 50.9 (IQR 42.1 to 75.1) mg l−1 in steady state, half-life of 10.9 (IQR 8.2 to 17.1) h and AUC (0–240 h) of 9,275 (IQR 7,139.4 to 15,794.8) mg l−1 h−1. The 30 drug-related treatment-emergent adverse events were evenly distributed between the treatment arms; 16 (53.5%) events occurred in the favipiravir group, and none of these were classified as severe or serious. Anemia was the most frequently observed adverse event in the ribavirin arm and vomiting in the favipiravir arm. All study participants survived and were successfully discharged from the isolation ward. This trial indicates favipiravir’s potential as a safe and well-tolerated alternative treatment regimen for LF and pharmacokinetic data suggest an optimized favipiravir regimen for future clinical evaluation. Clinicaltrials.gov: NCT04907682.